High rates of uncontrolled hypertensives have been reported in France as well as in other countries, partly owing to an inadequate management of hypertension by clinicians. The objectives of the study were (1) to describe the therapeutic decisions faced by general practitioners (GP) in hypertensives not controlled by fixed-dose combination antihypertensive therapy with a renin-angiotensin system (RAS) inhibitor and a diuretic (D) and (2) to evaluate the frequency with which ambulatory blood pressure monitoring (ABPM) is used in these patients. Each GP had to include five uncontrolled hypertensives on fixed-dose RAS inhibitor and D combination. A total of 2118 GPs included 9551 patients; 8643 patients were receiving at least one of the two drugs at a low dose (group 1) and the remaining 908 patients were receiving high doses of both drugs (group 2). The most common therapeutic choice was that of a new combination, either a fixed-dose in one pill or with separate preparations: 65% (n ¼ 5621) in group 1 and 56% (n ¼ 505) in group 2. An increase in dose was chosen in 28% of patients in group 1 (n ¼ 2467) and continuation of treatment without modification in 27% of patients in group 2 (n ¼ 242). A third active principle was only added in 2.5% of patients in group 1 (n ¼ 219) and 11% in group 2 (n ¼ 103). Ambulatory blood pressure monitoring was employed in 25% of patients (n ¼ 2413). An improvement in hypertension management should be expected from the implementation of the 2005 French guidelines.
Introduction
Although cardiovascular morbidity and mortality are lower in France than in Anglo-Saxon and Eastern countries, arterial hypertension remains a major Public Health problem, largely owing to its high incidence. A recent survey 1 estimated that eight million French people are undergoing treatment for hypertension (equivalent to 24% of the adult population). Moreover, around 80% of hypertensives are thought to be treated. 2 A high proportion of hypertensives are poorly controlled despite their treatment; Chamontin et al. 3 noted a particularly high failure rate (65-75%) in their study. [4] [5] [6] These poor results could be partly explained by inadequate management of antihypertensive treatments by clinicians. The French study, PHENOM-EN, 4 highlighted the discrepancy between the vigour of the antihypertensive treatment and the observed blood pressure (BP) control: 45% of patients with uncontrolled hypertension under treatment were receiving mono-or dual antihypertensive therapy. Similarly, the PRATIK study 5 demonstrated the under-use of combination therapies (in less than 2/3 high-risk hypertensives) and the suboptimal utilization of triple therapies (which in 25% of cases did not include diuretics).
French guidelines for the treatment of hypertensive patients, employed at the time of this study, 6 propose first intention antihypertensive treatment with single drug or fixed-dose combination therapy along with lifestyle and dietary measures: efficacy and tolerability to be evaluated over the first 2 months of treatment. When the first drug is well tolerated but has an insufficient antihypertensive effect, the preferred course of action should be the addition of a second active principle, preferably a thiazide if the first active principle does not belong to this class. These guidelines are less helpful when it comes to treating cases that are resistant to dual therapy.
Three strategic choices are available to the clinician: change the dual therapy; add a third active principle; or increase the dose of one or both components of the combination if the dose was not optimal.
To our knowledge, there are no published data on the attitude of general practitioners (GP) in France when confronted with this therapeutic decision. The present survey was thus designed to find out more about the decisions of French GP in the event of treatment failure with a dual therapy combining, in a fixed-dose form, a renin-angiotensin system (RAS) inhibitor: either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) combined with a diuretic. This is the most widely prescribed combination of antihypertensive drugs in France (47% of patients); in half of the patients, it is prescribed as a fixed-dose combined pill. 7 Angiotensin-converting enzyme inhibitors were introduced in France in the 1980s and the first ARB in 1995. Their efficacy in terms of reducing BP is comparable to other classes of antihypertensive, but the ARB is thought to be better tolerated. The morbidity/mortality benefits of the two classes are now well documented in different populations of hypertensives. [8] [9] [10] [11] [12] In the event of clinically judged resistance to a dual therapy, practitioners may also elect to substantiate the impression by using a method of BP measurement that eliminates the 'white-coat' effect, such as self-measurement or ambulatory BP measurement (ABPM). We also lack data on the frequency of use of these methods in such circumstances.
The primary objective of this survey was to explore the therapeutic decisions made by GP for hypertensive patients who are poorly controlled by fixed-dose antihypertensive therapy combining a RAS inhibitor and a diuretic.
The secondary objectives were to determine the clinical characteristics that influence the therapeutic decisions and to evaluate the frequency of use of ABPM in uncontrolled hypertensives.
Materials and methods
This cross-sectional observational study was conducted on a representative population of 2500 French GP selected at random from an independent database. Each doctor participating in the study had a 6-month period after the start date to include the first five patients seen in consultation who fulfilled the inclusion criteria: patients over 18 years of age with uncontrolled essential hypertension (BPX140/ 90 mm Hg) despite treatment for at least 6 months, at the same dose, with a fixed-dose therapy combining a RAS inhibitor (ACEI or ARB) and a thiazide diuretic. Patients with free combination therapy (i.e. the two active principles not combined in the same pill) and those receiving a fixed-dose combination therapy specifically indicated for the first intention treatment of hypertension were not included.
The patients were informed about the study and it was made clear that their participation in the study would not affect their treatment or follow-up; the doctors were free to choose their prescriptions and methods of follow-up.
Data collection
During the consultation, BP and heart rate were measured in the sitting position after a 5-min rest period. Three measurements were taken at 1-min intervals and only the last two were taken into account. 13 The class and dose of the two drugs in the current antihypertensive treatment were recorded, as well as the date on which this treatment was initiated.
The doctor had to record (three options: yes, no, don't know) the following associated cardiovascular pathologies and risk factors: active smoking, diabetes, dyslipidaemia (total cholesterol 42 g/l and/or triglycerides 42 g/l), history of coronary disease, history of a stroke or transient ischaemic accident, history of lower limb arteriopathy, renal insufficiency (serum creatinine 420 mg/l or 4177 mmol/l) and proteinuria.
They also had to indicate whether an ABPM had been performed during the last 12 months or was planned in the near future.
Finally, for each patient, the doctor had to record which of the following therapeutic decisions he would take: no change in treatment, change of dose (of diuretic, of RAS inhibitor or of both drugs), addition of a third active principle, discontinuation of current dual therapy and prescription of a new fixed-dose or free combination. If the doctor decided not to change the treatment, he had to indicate whether this choice was influenced by the tolerability of the treatment and/or refusal on the part of the patient to change, and/or an attempt to limit the number of doses of medication.
Data analysis
Statistical analysis was performed using SAS s software version 8.2 (Institute Inc., Cary, NC, USA). Questionnaires with data missing for BP on consultation, the nature and/or dose of treatments at inclusion, and the therapeutic decision were not included in the analysis. Similarly, patients presenting with a BP (mean of the second and third measurements taken during the consultation) of o140/90 mm Hg were excluded from the analysis. The quantitative data were described using means and standard deviation, and the categorical data by an overall number and the corresponding percentage. The description and analysis of the therapeutic decisions was classified as a function of current dual therapy and divided into two subgroups: group 1 ¼ patients on dual therapy at submaximal doses (including group 1A ¼ low-dose RAS inhibitor þ low-dose diuretic, group 1B ¼ high-dose RAS inhibitor þ low-dose diuretic, group 1C ¼ low-dose RAS inhibitor þ high-dose diuretic) and group 2 ¼ patients with dual therapy at maximal doses.
The therapeutic decision was summarized as a 'non-conservative approach' (prescription of a new combined or separate drug combination) or 'conservative approach' (no modification of treatment or change in dose or addition of a third active principle).
To investigate factors linked to the therapeutic decision or the use of an ABPM, quantitative variables were compared between the groups by analysis of variance (42 groups) or Student's t-test (two groups). The w 2 test was used for the categorical variables.
Multivariate analyses (logistic regression) were performed to identify factors that could independently explain the therapeutic decision or the use of ABPM. All of the variables with a P-value o0.15 were retained, and a stepwise selection procedure using entrance and exit thresholds of 0.05 was applied. A P-value o0.05 was considered significant.
Justification for the number of patients
The main objective of this survey was to define, with sufficient precision, the therapeutic decision as a function of the treatment of patients at consultation. With a population of 8500 patients in the group taking low doses of RAS inhibitor or diuretics, the precision was 1.1% for a treatment modality with a frequency of 50 and 0.6% if the frequency was 10%. With a population of 1000 patients in the group taking high doses of RAS inhibitor and diuretics, the precision was 3.1% for a treatment modality with a frequency of 50 and 1.9% if the frequency was 10%. Assuming a fall-out of 20% (dossiers not returned or unusable), a total of 12 500 patients were required.
Results
Of the 2500 selected GP, 2118 doctors participated in the study (mean age 4977 years; 30-73 years) and recruited 11 118 patients. Of these 11 118 patients, 254 patients presented with a mean BP of o140/ 90 mm Hg, and in 1313 patients, at least one of the following variables was missing: BP values at consultation (17 missing), nature and/or dose of treatments on inclusion (1296 missing), including 25 patients whose therapeutic decision was also missing.
Thus, 9551 patients (85.9%) were included in the analysis. Mean age was 64711 years. There were 5069 men (53.1%) and 4475 women (46.9%); gender was not indicated for seven patients.
The most common current antihypertensive treatment was the combination of low-dose RAS inhibitor with low-dose diuretic (5753 patients or 60.2% of the analysed population; group 1A). Next came the combination of high-dose RAS inhibitor and low-dose diuretic (2694 patients or 28.2% of the analysed population; group 1B), followed by the combination of high doses of both types of drug (9.5%, n ¼ 908, group 2). The combination of lowdose RAS inhibitor with high-dose diuretic was only noted in 2.1% of patients (n ¼ 196, group 1C).
The RAS inhibitor used was ARB in 54.6% of cases (n ¼ 5212).
The demographic and clinical characteristics of the whole population and of groups 1 and 2 are listed in Table 1 . The distribution of BPs according to their ANAES grades demonstrated a higher proportion of grade 1 and grade 3 hypertensives in group 2 than in subgroups 1A, 1B or 1C ( Figure 1 ).
The therapeutic decisions in the four treatment groups are illustrated in Figure 2 . Confronted with treatment failure, the practitioners' preferred approach was the prescription of a new combined fixed-dose or separate combination, regardless of the type of previous treatment: in 65.0% (n ¼ 5621) of patients who were not receiving maximal doses of dual therapy (group 1) and in 55.6% (n ¼ 505) of hypertensives receiving maximal dual therapy (group 2). Modification of the dose was chosen in 28.5% (n ¼ 2467) of patients in group 1 whereas a third active principle was rarely prescribed (2.5%; n ¼ 219).
In group 2, the continuation of treatment without modification was the second commonest strategy (26.7% of patients) whereas a third active principle was only added in 11.3% of patients. A change in dose was indicated in 6.4% of patients, equivalent to 58 patients, 31 of whom presented with a poor tolerability.
Thus, the 'non-conservative' approach, that is, the choice of a new combined or separate drug combination, was more common than the conservative approach, notably in groups 1B (77.0% of cases, n ¼ 2075) and 1C (70.4% of cases, n ¼ 138), and in a smaller proportion of groups 1A (59.2%, n ¼ 3408) and 2 (55.6%, n ¼ 505).
The effects of the patients' demographic and clinical characteristics (BP, cardiovascular risk factors and concurrent clinical pathologies) and the class of the RAS inhibitor used on the doctor's therapeutic decision are shown in Table 2a and b for groups 1 and 2, respectively.
The factors influencing a non-conservative approach (vs conservative) retained in the multivariate analysis are listed in Table 3a and b. Thus, in group 1, the non-conservative approach was independently related to the highest BPs, to systolicdiastolic (SD) hypertension, to the use of an ACEI rather than an ARB and to the duration and dosage of the current dual therapy. Abbreviations: RAS, renin-angiotensin system; TIA, transient ischaemic accident.
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In the group of patients receiving the high-dose combination (group 2), multivariate analysis demonstrated that the severity of the hypertension (grade 2 vs grade 1), the SD hypertension type, the use of an ACEI and a duration of fixed-dose combination therapy of more than 3 months were factors inducing a non-conservative approach.
The doctors declared that ABPM had been conducted in the last 12 months or was planned in the near future in 2413 patients, equivalent to 25.3% of the study population. The proportion of patients undergoing ABPM was similar in all treatment groups: 26.0% in group 1A (n ¼ 1495), 23.0% in group 1B (n ¼ 619), 33.2% in group 1C (n ¼ 65) and 25.8% in group 2 (n ¼ 234). As shown in Table 4 , after adjustment, ABPM was requested more often in younger patients, those with higher BP figures, those undergoing fixed-dose combination therapy for more than 3 months, cases with SD hypertension and in the presence of associated risk factors or clinical pathologies (dyslipidaemia, diabetes, smoking, history of stroke, transient ischaemic attack or coronary disease).
Finally, in the subgroup of patients whose treatment was not altered, the doctors cited the following factors as influencing this therapeutic decision: group 1: tolerability in 192 cases (57.1%), patient's refusal to change in 78 cases (23.2%) and a desire to limit the number of doses in 85 cases (25.3%). In group 2, the distribution was as follows: tolerability for 186 cases (76.9%), patient's refusal to change in 23 cases (9.5%) and a desire to limit the number of doses in 88 cases (36.4%).
Of note, 285 patients (3.0%) spontaneously reported at least one adverse event during the visit: 241 patients in group 1 (2.8%) and 44 patients in group 2 (4.8%).
Discussion

Uncontrolled hypertension
The results of the treatment of hypertensive patients in France are relatively disappointing. 3, 5, 7 Thus, out of the hypertensives receiving treatment in the French subgroup of the MONICA study, 14 which included all types of patients (35-64 years of age), the 140/90 mm Hg goal was only attained in men in 21% of the 35 to 44-year-old range, 11% of the 45-54 age group and 8% of the 55-64 age group. In women, the control rate was 28, 16 and 15% in these three age groups, respectively. The IHPAF survey 15 of patients, followed up by the French medical service for health and safety in the workplace, confirmed this poor rate of BP control in treated hypertensives: only 13% of men and 33% of women attained the objective. A rate of 24% was reported in a survey carried out in general practice. 3 A similar failure rate has been reported in other countries: the rate of control is less than 6% in the United Kingdom, 16 50% in Scotland but with a target of 160/95 mm Hg 17 and 31% in the United States. In the latter, poor results were noted more often in women, Mexican-Americans and patients over 60 years of age. 18 There are several reasons for these poor results: 19 Some are linked to the patients themselves and include a lack of motivation, poor adherence, poor adaptation to secondary effects, even very mild ones, excess salt consumption or excessive alcohol intake, etc. This last point was examined in particular depth in our study, the primary aim of which was to analyse the customary attitudes of practitioners, which is an essential starting point for the instigation of properly adapted training programmes.
Furthermore, this study provides us with a description of the profile of a sample of nonnormalized patients; of particular note is the marked prevalence in our survey of the combination of Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HT, hypertension; RAS, renin-angiotensin system; SD hypertension, systolic-diastolic hypertension.
Only the significant factors were included in this table; the following factors were not significant: sex, age, BMI, smoking habit, diabetes, dyslipidaemia, history of coronary disease, stroke, TIA, lower limb arteriopathy, renal insufficiency and proteinuria. hypertension and dyslipidaemia (63% of patients), whereas 28% of patients in the FLAHS study 1 were treated for both hypertension and dyslipidaemia. Similarly, diabetes was associated with hypertension in 22% of cases in our population, compared with only 8% of cases in the FLAHS survey. We therefore observed, in common with other authors, a higher prevalence of associated risk factors in uncontrolled hypertensives. In the experience of Asmar et al., 20 based on 61 108 patients seen in healthcare centres, elevated BP was associated with at least one other risk factor (most commonly hypercholesterolemia) in 84% of men and 77% of women, and with at least two other risk factors in 23% of men and 10% of women. Amar et al. 5 demonstrated that the control of hypertension decreased as the number of risk factors increased: only 27% of patients were controlled in the group presenting with at least three associated risk factors or target organ damage, compared to 43% in the group without associated risk factors.
Management of resistance to combined therapy
In our survey, doctors were asked what they might do with a particular patient they had just seen. Clearly, faced with a failure of combined therapy, they favoured the use of a new fixed-dose or separate combination, that is, a therapeutic 'switch'. The latter was chosen in 65% of patients who were not receiving maximal doses of the dual therapy, and in 56% of those who were receiving maximal doses of both drugs.
This therapeutic decision, which can be described as 'non-conservative', was more common in the patients with the highest BP, those with SD hypertension, those whose dual therapy included an ACEI and those whose treatment was longstanding. We also found that in patients on submaximal doses of combined therapy, the actual dosages had an influence, with a new combination being chosen more often if one of the drugs of the dual therapy was at its maximal dose. Associated risk factors and clinical pathologies were not found to influence the doctors' decision.
Among the various forms of conservative approach, dosage was altered in 28% of patients receiving submaximal doses, whereas a third active principle was rarely added in this subgroup (2.5%). In patients receiving maximal doses, a third active principle was also little prescribed (11% in this group).
Arguments for and against each of the various strategies can be found in the literature.
Increasing the doses. This is not always the best solution, as it is often associated with an exacerbation of secondary effects, and not necessarily with any substantial increase in antihypertensive action.
Law et al., 21 pooling the results of 354 randomized trials, demonstrated the heterogenicity of the dosetolerance relationship between the different classes: although an increase in dosage is strongly correlated with an increase in secondary effects for thiazide diuretics, beta-blockers and calcium channel inhibitors, it does not alter the secondary effects of ACEI (principally coughing), whereas ARB are equally well tolerated at high and low doses.
In a population of hypertensive patients over 65 years of age, Morgan et al. 22 demonstrated that in comparison with a single dose, doubling the dose was only accompanied by a significant additional decrease in BP with amlodipine (5 mg), but not with atenolol (25 mg), enalapril (20 mg) or hydrochlorothiazide (HCTZ, 25 mg). It should be noted that the 25 mg dose of HCTZ, considered as single by Morgan, is in fact the highest dose available in fixeddose combinations. Other authors have demonstrated that this 25 mg dose was significantly more effective than the 12.5 mg dose at lowering BP, and also note the absence of any substantial increase above 50 mg. 23 It should also be noted that it is only above 25 mg that HCTZ significantly increases basal plasma renin activity. 24 In a previous study, we demonstrated that the prescription of a combination of valsartan þ 25 mg HCTZ in patients who were not controlled by a combination of ARB þ 12.5 mg HCTZ normalized an additional 23% of patients. 25 In the present study, the majority of doctors who chose to increase the dose in patients receiving the two drugs at low doses increased the dose of both the RAS inhibitor and the diuretic.
Treatment switch. The advantage of switching treatments after a monotherapy has been well documented by Dickerson et al., 26 who demonstrated in a crossover study that patients who responded to diuretics and calcium channel blockers were little or not at all responsive to ACEI and beta-blockers, and vice versa. This concept has now been incorporated into the BHS guidelines. 27 However, switching in the event of dual therapy failure is only mentioned in the literature in combination with a change in the dose of one of the components, as indicated above. 25 It is difficult to identify practitioners' motives for switching treatment. Thus, in a population-based study on the renewal of prescriptions at 12 months in newly treated hypertensives, Bloom 28 recorded a continuation of treatment in 64% of cases with ARB, 58% with ACEI, 50% with calcium channel blockers, 43% with beta-blockers and 38% with the thiazides. However, these figures had no correlation with the switch rate, which was between 6 and 9% for each of these drug classes. A recent Canadian study gave similar results for continuation of treatment at 90 days. 29 However, in a large Taiwanese study, with more than 500 000 patients, the switch rate was found to be much greater than in Bloom et al.'s experience: 29% with ACEI and diuretics, 23% with beta-blockers and 21% for the calcium channel blockers. 30 A switch was therefore the most common therapeutic decision of the doctors in our survey, given that a switch was defined as a change to another therapeutic class or a change of drug within the same class. The link we found between 'non-conservative approach' and SD hypertension could illustrate that patients with SD hypertension are considered by GP at higher risk than those with isolated systolic hypertension. Such a misconception has been frequently reported in the literature. 31 The addition of a third active principle. Law et al. 21 have demonstrated the advantages of this strategic choice. They found that a synergistic triple therapy at half-doses was not only significantly more effective on BP than a dual therapy prescribed at half-doses (À19.9/10.7 vs À13.3/7.3 mm Hg) but that one could also expect a significantly greater reduction in cerebral risk (À63 vs À49%) and coronary disease (À46 vs À34%). For example, the standard doses are 2.5 mg for bendroflumethiazide, 50 mg for atenolol, 10 mg for lisinopril, 80 mg for valsartan and 5 mg for amlodipine.
In accordance with the work of Dickerson et al., the third active principle to add in the event of an insufficient response to a RAS inhibitor þ diuretic combination can only be a calcium channel blocker.
Curiously, the doctors in our study rarely prescribed a third drug. They may not have wished to increase the number of different drug doses or maybe they had previous experience of poor tolerance to a calcium channel blocker.
Finally, the absence of any change in treatment was seen in a significant proportion of cases in our study, especially in patients receiving the dual therapy at maximal doses. Thus, the doctors settle for BP values that are higher than the objective, despite the fact that the advantages of achieving these objectives have now been established. 32, 33 This inertia is justifiably criticized in the literature. 34 The main reason for not modifying the treatment is tolerability. Good tolerability is indeed essential to reduce the risk of intentional poor adherence 35 and, in the same proportion, condition patient satisfaction for correct BP control, as demonstrated in an American survey in patients contacted by e-mail. 36 Doctors also want to try and limit the number of doses; indeed the risk of decreased adherence due to an increase in the number of daily doses is well recognized. 37 Blood pressure measurement outside the office The numerous sources of error associated with the clinical measurement of BP justify self-measure or ABPM in the event of an apparently poor response to antihypertensive treatment.
The SHEAF study 38 revealed that discrepancies between self-measurement and clinical measurement data are common: 14% of patients who were normalized by the treatment according to the first method were not according to the second method, thus defining 'white coat HT', whereas 9% were in the opposite situation, characteristic of 'masked' HT. This study also demonstrated that the prognosis for these masked hypertensives was even poorer than that of patients considered as poorly controlled with both methods.
We specifically questioned our practitioners about ABPM, whose contribution has also been well documented in apparently resistant or non-responsive hypertensives: in the study of Brown et al., 39 nearly one-quarter of patients sent to specialized clinics for poorly controlled BP despite receiving three drugs actually had an ABPM during activity of o135/85 mm Hg. In common with self-measurement, the prognostic value of ambulatory BP is now well documented. 40, 41 European guidelines specify that information provided by ABPM should not replace information from clinical measurements, but should be considered as complementary, given that clinical BP and ambulatory BP over 24 h are only roughly correlated. 42 The JNC 7 retains indications for ABPM, including the evaluation of hypertension in cases with no target organ damage (to demonstrate a possible white-coat effect), and to investigate patients with an apparently resistant hypertension. According to recent French guidelines, 43 out of office BP measurements are recommended to be performed in all elderly patients as well as in patients with mild-to-moderate hypertension and without target organ damage.
In our study, the implementation rate of ABPM in the last 12 months or planned in the near future appeared relatively high as it was prescribed in one out of four patients. This was independent of the dose of the dual therapy, but was however more common in younger patients, in those with higher BP, with SD hypertension, with recently instigated dual therapy (less than 3 months) and in those with associated risk factors and cardiovascular pathologies.
Conclusion
The findings of this study show that GP do not favour prescription of a third active principle in patients who are not normalized by a fixed-dose therapy combining a RAS inhibitor and a diuretic, despite the recognized efficacy of this strategy. They prefer to change the treatment: that is, to increase dosage and/or to switch to another class or within the same class. The choice of a treatment that is often too weak can be explained by poor knowledge of BP objectives and of the demonstrated benefits of achieving these targets on cardiovascular morbidity and mortality. It can also be explained by the desire to maintain good tolerability and limit the number of doses to maintain good patient adherence. Ambulatory blood pressure monitoring is employed in one-quarter of cases, a proportion that is satisfactory, but which could still be improved.
The new French guidelines for hypertension management 43 provide clinicians with updated recommendations regarding therapeutic strategies. Their widespread implementation should reasonably result in minimizing the rate of suboptimal treatment in hypertensive patients.
